<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457819</url>
  </required_header>
  <id_info>
    <org_study_id>SEP360-310</org_study_id>
    <nct_id>NCT02457819</nct_id>
  </id_info>
  <brief_title>Dasotraline Pediatric Extension Study</brief_title>
  <official_title>An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label 26 week extension study for subjects who completed SEP360-202.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, flexibly-dosed, 26 week extension study in children and adolescents
      with ADHD who have completed 6 weeks of double-blind treatment in the core study (SEP360
      202). This study will evaluate the long-term safety and tolerability of dasotraline in this
      population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2015</start_date>
  <completion_date type="Actual">February 2, 2017</completion_date>
  <primary_completion_date type="Actual">February 2, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of overall AEs (or SAEs), and AEs (or SAEs) leading to discontinuation</measure>
    <time_frame>26 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory evaluations (serum chemistry)</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory evaluations (hematology)</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory evaluations (lipid panel)</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory evaluations (thyroid function panel)</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory evaluations (urinalysis)</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory evaluations (sex hormones)</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluations (physical examination)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluations (vital signs)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluations (body height and weight)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluations (Tanner Staging)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluations (12 lead ECG)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of suicidal ideation using the C SSRS.</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of suicidal behavior using the C SSRS.</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ADHD RS IV HV total score.</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the inattentiveness and hyperactivity subscales of the ADHD RS IV HV.</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI S score.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Conners 3 P total score and subscale scores (Oppositional, Cognitive problems, Hyperactivity, and ADHD Index).</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSHQ total score and 8 subscale scores (bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep disordered breathing, and daytime sleepiness).</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WFIRS-P total score and 6 domain scores (family, school learning behavior, life skills, child's self-concept, social activities, and risky activities).</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess potential withdrawal symptoms following discontinuation of dasotraline using the following assessments DESS scale and the PWC</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Dasotraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasotraline 2, 4, 6 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasotraline</intervention_name>
    <description>Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed</description>
    <arm_group_label>Dasotraline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one of the subject's parent/legal guardian must give written informed
             consent, including privacy authorization, prior to study participation. The subject
             will complete an informed assent prior to study participation.

          -  Subject and subject's parent/legal guardian are judged by the investigator to be
             willing and able to comply with the study procedures and visit schedules.

          -  Subject has completed all required assessments for Week 6 of the core study.

          -  Subject has not taken any medication other than the study drug for the purpose of
             controlling ADHD symptoms during the core study.

          -  Subject, if female, must not be pregnant or breastfeeding.

          -  Female subject: must be unable to become pregnant (eg, premenarchal, surgically
             sterile, etc);

        -OR-

          -  practice true abstinence (consistent with lifestyle) and must agree to remain
             abstinent from signing informed consent/assent to at least 14 days after the last dose
             of study drug has been taken; -OR-

          -  is sexually active and willing to use a medically effective method of birth control
             from signing informed consent/assent to at least 14 days after the last dose of study
             drug has been taken.

          -  Male subject must be willing to remain sexually abstinent (consistent with lifestyle)
             or use an effective method of birth control, from signing informed consent/assent to
             at least 14 days after the last dose of study drug has been taken.

          -  Any subject whose weight is less than or equal to 21 kg at the OL Baseline visit
             should be discussed with the medical monitor prior to enrollment.

          -  Subject and subject's parent/legal guardian must be able to fully comprehend the
             informed consent/assent form (as applicable), understand all study procedures, and be
             able to communicate satisfactorily with the Investigator and study coordinator.

        Exclusion Criteria:

          -  -Subject is considered by the investigator to be at imminent risk of suicide, injury
             to self or to others, or damage to property.

          -  Subject answers &quot;yes&quot; to &quot;Suicidal Ideation&quot; item 4 (active suicidal ideation with
             some intent to act, without specific plan) or item 5 (active suicidal ideation with
             specific plan and intent) for any lifetime history on the C SSRS Children's &quot;Since
             Last Visit&quot; assessment at OL Baseline.

          -  Subject has a clinically significant abnormality including physical examination, vital
             signs, ECG, or laboratory tests that the investigator in consultation with the medical
             monitor considers to be inappropriate to allow participation in the study.

          -  Subject has a positive urine drug screen (UDS) or breath alcohol test at OL Baseline.

          -  Subject or parents/legal guardian has commitments during the study that would
             interfere with attending study visits.

          -  Subject is at high risk of non-compliance in the investigator's opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dasotraline Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harmonex Neuroscience Research, Inc</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProScience Research Group</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Trials, Inc.</name>
      <address>
        <city>Wildomar</city>
        <state>California</state>
        <zip>92595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indago Research Health Center, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates, LLC</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baber Research Group, Inc.</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>630-896-3530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goldpoint Clinical Research, LLC.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pedia Research,LLC</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pedia Research,LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurobehavioral Medicine Group, Clinical Trials Division</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials group at the Rochester Center for Behavioral Medicine</name>
      <address>
        <city>Rochester Hills</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Psychiatric Associates - Midwest Research Group</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates, Inc.</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richarmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati/Department of Psychiatry and Behavioral Neuroscience</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cyn3rgy Research</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin P.C.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayou City Research, Ltd.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Trials, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Runner Research, Ltd.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <disposition_first_submitted>January 5, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 5, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 10, 2018</disposition_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

